0001213900-22-018749.txt : 20220407
0001213900-22-018749.hdr.sgml : 20220407
20220407182659
ACCESSION NUMBER: 0001213900-22-018749
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220405
FILED AS OF DATE: 20220407
DATE AS OF CHANGE: 20220407
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chen Bihua
CENTRAL INDEX KEY: 0001599214
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39630
FILM NUMBER: 22814945
MAIL ADDRESS:
STREET 1: C/O CORMORANT ASSET MANAGEMENT, LP
STREET 2: 200 CLARENDON STREET, 52ND FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MoonLake Immunotherapeutics
CENTRAL INDEX KEY: 0001821586
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: DORFSTRASSE 29
CITY: ZUG
STATE: V8
ZIP: 6300
BUSINESS PHONE: 41 41 510 8022
MAIL ADDRESS:
STREET 1: DORFSTRASSE 29
CITY: ZUG
STATE: V8
ZIP: 6300
FORMER COMPANY:
FORMER CONFORMED NAME: Helix Acquisition Corp
DATE OF NAME CHANGE: 20200818
4
1
ownership.xml
X0306
4
2022-04-05
0
0001821586
MoonLake Immunotherapeutics
MLTX
0001599214
Chen Bihua
C/O HELIX ACQUISITION CORP.
200 CLARENDON STREET, 52ND FLOOR
BOSTON
MA
02116
0
0
1
0
Class A Ordinary Shares
2022-04-05
4
C
0
2785000
0
A
3215000
I
See footnote
Class A Ordinary Shares
2022-04-05
4
P
0
2850000
10.00
A
2850000
I
See footnote
Class B Ordinary Shares
2022-04-05
4
C
0
2785000
D
Class A Ordinary Shares
2785000
0
I
See footnote
Helix Holdings LLC is the record holder of these securities reported. Bihua Chen is the manager of Helix Holdings LLC and has voting and investment discretion with respect to the securities held of record by Helix Holdings LLC. Ms. Chen disclaims any beneficial ownership of the securities held by Helix Holdings LLC other than to the extent of any pecuniary interest she may have therein, directly or indirectly.
Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.
Each of the Issuer's Class B Ordinary Shares were convertible into Class A Ordinary Shares upon consummation of the Issuer's initial business combination and had no expiration date. In connection with the consummation of the Issuer's initial business combination ("Business Combination") and pursuant to the Business Combination Agreement dated as of October 4, 2021, by and between the Issuer, MoonLake Immunotherapeutics AG, and the other parties thereto (the "Business Combination Agreement"), such Class B Ordinary Shares automatically converted into an equal number of Class A Ordinary Shares.
In connection with the Business Combination, the Cormorant Funds entered into Subscription Agreements with the Issuer dated as of October 4, 2021 and March 31, 2022, pursuant to which, at the closing of the Business Combination, the Cormorant Funds purchased an aggregate of 2,850,000 Class A Ordinary Shares at a price of $10.00 per share.
/s/ Bihua Chen
2022-04-07